Development and characterization of a potent immunoconjugate targeting the Fn14 receptor on solid tumor cells.
about
The TWEAK receptor Fn14 is a potential cell surface portal for targeted delivery of glioblastoma therapeuticsAnti-tumor activities and apoptotic mechanism of ribosome-inactivating proteinsAdvances in anticancer immunotoxin therapyRegulation of fibroblast growth factor-inducible 14 (Fn14) expression levels via ligand-independent lysosomal degradationTWEAK-independent Fn14 self-association and NF-κB activation is mediated by the C-terminal region of the Fn14 cytoplasmic domainDevelopment of human serine protease-based therapeutics targeting Fn14 and identification of Fn14 as a new target overexpressed in TNBC.Minimizing the non-specific binding of nanoparticles to the brain enables active targeting of Fn14-positive glioblastoma cells.Fn14 receptor promotes invasive potential and metastatic capacity of non-small lung adenocarcinoma cells through the up-regulation of integrin α6Surface plasmon resonance as a high throughput method to evaluate specific and non-specific binding of nanotherapeutics.Cdc42 and the guanine nucleotide exchange factors Ect2 and trio mediate Fn14-induced migration and invasion of glioblastoma cellsThe TWEAK receptor Fn14 is a therapeutic target in melanoma: immunotoxins targeting Fn14 receptor for malignant melanoma treatmentExtracellular tissue transglutaminase activates noncanonical NF-κB signaling and promotes metastasis in ovarian cancerAntitumor activity of a humanized, bivalent immunotoxin targeting fn14-positive solid tumorsDesign and In Vivo Characterization of Immunoconjugates Targeting HIV gp160.The TWEAK-Fn14 system as a potential drug target.Role of the TWEAK-Fn14-cIAP1-NF-κB Signaling Axis in the Regulation of Myogenesis and Muscle HomeostasisTWEAK-Fn14 Cytokine-Receptor Axis: A New Player of Myocardial Remodeling and Cardiac FailureTargeted therapies in bladder cancer: an overview of in vivo research.TWEAK/Fn14 signaling in tumors.Construction and characterization of gelonin and saporin plasmids for toxic gene-based cancer therapy.Design of an EGFR-targeting toxin for photochemical delivery: in vitro and in vivo selectivity and efficacy.α-sarcin and RNase T1 based immunoconjugates: the role of intracellular trafficking in cytotoxic efficiency.Synergistic antitumor activity from two-stage delivery of targeted toxins and endosome-disrupting nanoparticlesBioinformatic prediction and experimental validation of a PE38-based recombinant immunotoxin targeting the Fn14 receptor in cancer cells.Elevated expression of Fn14 in non-small cell lung cancer correlates with activated EGFR and promotes tumor cell migration and invasion.TWEAK/Fn14 Axis-Targeted Therapeutics: Moving Basic Science Discoveries to the Clinic.Protective Role for TWEAK/Fn14 in Regulating Acute Intestinal Inflammation and Colitis-Associated Tumorigenesis.Enhanced cellular uptake and tumor penetration of nanoparticles by imprinting the "hidden" part of membrane receptors for targeted drug delivery.Quercetin-loaded nanomicelles to circumvent human castration-resistant prostate cancer in vitro and in vivo.FN14 expression correlates with MET in NSCLC and promotes MET-driven cell invasion.
P2860
Q26795601-65F69C41-6F66-4DBB-983D-8A0E74AC3722Q26799861-FFCCED14-473A-4000-950F-FD54854D4ED9Q28085551-8DEABB5E-D94E-4A62-A2B1-16E7DDD5C908Q33676528-BDAAAA5B-E292-4981-BABC-A8697820B9FFQ34764239-EC22AAF5-1D34-4305-B21E-E9CBD70B4DF7Q34773994-171380CC-BCFE-417F-98C4-675457A0CE18Q34785621-7B018376-8DA9-41C3-B2D8-A6483C2E57BAQ35683636-3D27B4CE-9933-439A-8657-F9B98A7B2DEBQ36307546-481ECCA6-4273-452F-8360-866B97038B4CQ36452209-702561A3-B750-4D19-A0AA-A3DA55BD9B2FQ36691896-2E3C297B-03BC-4CFF-9629-E9E6A44EECA0Q36879220-C517C32D-8204-4A2F-AACC-B11FB44B7A4BQ37247862-CA07C915-36EC-41B0-B8BF-F0925CC0EEB5Q37593171-C13F06AA-5525-4E4B-8373-DC623FEC6431Q38129961-CFA05AA5-E0BE-4D2B-AA47-5F25BBC050BBQ38189358-1D7431AF-23F0-4783-ACE9-48FB25A0DBBDQ38194552-7915E7CC-8620-4878-823D-F1C8D1D2F6F3Q38590471-146422AF-5CB9-491D-BCAD-0FE615A7FCFDQ38668064-6EB53444-452B-48C3-87EA-FBF580AC0E18Q38783865-18BF7306-013B-41D3-8452-00F129BE9D37Q38909313-0E90B9BC-DC02-4566-8217-D8B94BA79A08Q38932236-1D103DE8-2096-4C24-8B7B-9EC64CCEB818Q39187821-C7CDC26B-5EEB-45E3-9F36-D362A86FF8A5Q40267233-C188A788-77D9-4854-9B47-9CED097793D3Q41865343-F36D1C5E-7BA2-421D-9677-5514D628369FQ42004462-6D93678B-1706-4A67-B7FB-CD2F7D98AE29Q43238527-14FBE45F-6B79-4534-ACF9-F16B203C07A0Q50003210-98B4AAB9-CDD9-47D5-82F2-D28667D72464Q50880613-A6A00622-87FB-41C7-B674-22559667CD38Q53058993-27EBC5DF-5ACD-4016-8FC8-54687198C1E8
P2860
Development and characterization of a potent immunoconjugate targeting the Fn14 receptor on solid tumor cells.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Development and characterizati ...... receptor on solid tumor cells.
@ast
Development and characterizati ...... receptor on solid tumor cells.
@en
type
label
Development and characterizati ...... receptor on solid tumor cells.
@ast
Development and characterizati ...... receptor on solid tumor cells.
@en
prefLabel
Development and characterizati ...... receptor on solid tumor cells.
@ast
Development and characterizati ...... receptor on solid tumor cells.
@en
P2093
P2860
P1476
Development and characterizati ...... receptor on solid tumor cells.
@en
P2093
Hideo Yagita
Jeffrey A Winkles
John W Marks
Lawrence H Cheung
Michael G Rosenblum
Walter N Hittelman
P2860
P304
P356
10.1158/1535-7163.MCT-11-0161
P577
2011-05-17T00:00:00Z